Navigation Links
Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer

Same Day Procedure May Transform Treatment Approach to Retinoblastoma

BOCA RATON, Fla., July 28 /PRNewswire-USNewswire/ -- Expanded results of a study conducted on children with eye cancer (retinoblastoma) shows that chemotherapy delivered through endovascular (through the vessel) means not only successfully cures the cancer in a majority of cases, but achieves this cure with preserved vision. Study outcomes were presented this week at the Society of NeuroInterventional Surgery (SNIS) 6th Annual Meeting in Boca Raton, FL by lead author Pierre Gobin, Professor of Radiology in Neurosurgery and Neurology at the Weill Cornell Medical Center at New York Presbyterian Hospital in New York City.

"This is an exciting development in the neurointerventional community, as results prove that chemotherapy delivered through endovascular techniques is a powerful tool in addressing the most severe forms of retinoblastoma," says Gobin, who says that the study is the product of teamwork between New York Presbyterian Hospital and the Eye Cancer Center of Memorial Sloan Kettering Cancer Center, New York City, with support from David Abramson, M.D., Brian Marr, M.D., Ira Dunkel, M.D. And Scott Brodie, M.D.

Retinoblastoma, the seventh most common pediatric cancer, is a malignant eye tumor in children that arises in cells in the developing retina. Typically, this cancer is associated with a late diagnosis as one of the only symptoms, a white pupil replacing the normal black, presents when the tumor occupies over one-third of the eye. Conventional therapy for this cancer includes laser treatment, as well as techniques that utilize extreme cold to freeze and destroy abnormal cells or deliver radioactive substances in timed intervals to kill the tumor. If these treatments fail, physicians resort to intravenous chemotherapy or radiation therapy. Despite this wide array of treatment options, however, a late diagnosis often requires the removal of the eye.

According to Gobin, the study was initiated in 2006 to determine if chemotherapy delivered through endovascular methods (through a catheter inserted in the groin and threaded up through the vessels to the site of the tumor), otherwise known as chemosurgery, would produce better outcomes for retinoblastoma patients, including preserving the eye and vision as well as avoiding intravenous chemotherapy, which is administered over the course of six months to a year and can be frequently associated with port infections and sickness for the duration of that time. Since the study was initiated, 49 children, ranging in age from 1 month to 10 years, have been treated with this technique. Of this number, all suffered from advanced retinoblastoma and were candidates for removal of the eye. Additionally, half of the patients had already failed prior conventional treatments, including intravenous chemotherapy or radiation therapy; nine patients had already had an eye removed.

Study participants were chosen following an eye examination under anesthesia, allowing physicians to confirm the diagnosis and determine the extent of the disease. For those who qualified, chemosurgery was performed soon thereafter, and was repeated every three to four weeks, up to six times.

To date, 144 chemosurgeries have been performed, which equates to a mean of three per patient. Results indicate that physicians were able to technically perform the procedure successfully in almost every case. Short-term follow-up, occurring after six or more months of stability after the last treatment, showed that of 27 eyes, 21 are cured (77 percent) and 13 are cured with preserved vision (48 percent). Six eyes could not be saved. Overall, of the population of eyes that were treated, 50 percent of patients would have lost an eye on conventional treatment; of those who kept an eye, a majority would not have experienced useful vision. With chemosurgery, only ten percent of patients lost an eye.

In general, patients tolerated the procedure well with minimal side effects that resolved once

addressed. In only four out of 46 eyes treated did severe complications occur which eventually led to blindness. All four eyes had received previous extensive treatment consisting of intravenous chemotherapy and radiation therapy.

Due to the overwhelming success observed with chemosurgery, Gobin says this treatment option has considerably reduced the number of conventional treatments, including the toxic intravenous chemotherapy, and most significantly, the number of eye losses. "The results really do have the potential to change the entire treatment approach to advanced retinoblastoma. In our center, chemosurgery is now the first line of treatment for this potentially devastating condition."

Retinoblastoma occurs in approximately 350 - 400 children each year. Approximately 80 percent of patients are diagnosed under 3 years of age.

About SNIS

SNIS members are neurointerventional practitioners with backgrounds in neuroradiology, neurosurgery and neurology that come together in the shared discipline of neurointerventional surgery. Our practitioners specialize in minimally invasive and endovascular procedures to treat stroke, aneurysms, carotid stenosis and spine fractures. Over the past two decades, our physicians have made numerous contributions to the neurosciences including: advancing stroke treatment through catheter based therapy; innovating endovascular coiling for aneurysms; pioneering interventional procedures to treat fractures in the spine; and initiating the first-ever stroke registry to track procedural success in the treatment of acute stroke. More information on SNIS and our members' treatment specialties may be found at

SOURCE Society of NeuroInterventional Surgery
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A Heart Healthy Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age
2. iJET Provides Additional Services in Response to Ongoing H1N1 Influenza A (Swine Flu) Developments
3. UPMC Health Plan Provides Ongoing Support of HEALTHY Armstrong Initiative
4. Recent Study Disproves General Hospitals Ongoing Criticism of Physician Owned Hospitals, Shows Little to No Effect on General Hospitals Business, Reports Physician Hospitals of America
5. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
6. Ongoing worldwide shortage of medical isotopes could threaten patient care, says expert
7. Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning
8. Stimulus Bill Requires Modification in U.S. Senate to Better Protect Seniors Ongoing Access to Quality Nursing Home Care
9. Window World Cares Raises $160,000 for St. Jude Childrens Hospital, Commits to Ongoing Support
10. New Study Disputes Ongoing Controversy Over Memory Screenings
11. Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing Tuskegee Effect When Recruiting Minorities for Research Studies
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: